

RESEARCH

Open Access



International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the *SIGNATURE* initiative

Alessandra Dodich^{1*} , Andrea Panzavolta² , Giulia Funghi¹ , Claudia Meli¹ , Cristina Festari³ , Thanos Chatzikostopoulos⁴ , Christian Chicherio⁵, Florencia Clarens⁶ , Fabricio Ferreira de Oliveira⁷ , Marco Filardi⁸ , Agustin Ibanez^{9,10,11,12,13} , Laura Invernizzi¹⁴, Thibaud Lebouvier¹⁵ , Giancarlo Logroscino¹⁶ , Sarah E. MacPherson¹⁷ , Riccardo Manca¹⁸ , Camillo Marra^{19,20} , Jordi A. Matias-Guiu²¹ , Maxime Montembeault²² , Costanza Papagno¹ , Simone Pomati²³ , Mario Possenti²⁴, Olivier Piguet²⁵ , Leonardo Sacco²⁶ , Ann-Katrin Schild²⁷ , Marc Sollberger²⁸ , Miguel Tábuas-Pereira^{29,30} , Marianna Tsatali⁴ , Magda Tsolaki⁴ , Esther van den Berg³¹ , Stefano F. Cappa² , Maxime Bertoux³² , Fiona Kumfor³³ , Jan Van den Stock³⁴ , Marina Boccardi^{35,36,37} , Kathleen Anne Welsh-Bohmer³⁸  and Chiara Cerami^{2,39}  on behalf of SIGNATURE Consortium

Abstract

Background Socio-cognitive assessment in neurocognitive disorders (NCDs) is rare in clinical practice and no consensus exists as to a uniform operationalization of socio-cognitive measures for NCDs in memory clinics. The *SIGNATURE* initiative aims to optimize the use of socio-cognitive measures in memory clinics, defining expert recommendations. We report consortium guidelines for the use of socio-cognitive measures in NCDs based on available evidence from the literature and the current state of practices in memory clinics.

Methods Using a Delphi consensus method supported by a literature review and the results of an international survey, 22 specialists defined recommendations for the context of use, relevance in NCD diagnosis, priorities for future research and facilitators/obstacles of socio-cognitive assessment in major and mild NCDs.

Results Overall, panelists recommended social cognition testing in routine diagnostic assessment to evaluate both socio-cognitive and socio-behavioral alterations. A set of clinical, methodological, implementation and external factors facilitating or hampering the use of socio-cognitive tasks was identified.

Conclusions This is the first focused endeavor to favor the implementation of socio-cognitive assessment, which is required by DSM-5 but seldom performed despite clear evidence of its clinical relevance for diagnosis and care. Our

*Correspondence:
Alessandra Dodich
alessandra.dodich@unitn.it

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

results provide an initial set of recommendations, refinable through the future actions of the *SIGNATURE* initiative. Future collaborative clinical research projects should overcome current limitations and foster the use of ecological and cross-culturally validated measures in clinics.

Keywords Cognitive Assessment, Social cognition, Recommendations, Neurocognitive disorders

Introduction

Social cognition, which encompasses the cognitive processes underlying social interactions, is a critical domain affected in various neurocognitive disorders (NCDs), including Alzheimer's disease (AD) and related disorders (ADRD) [1]. Despite its recognized importance, assessment of the social cognition domain in clinical settings remains inconsistent and fragmented [2–5]. This variability might hinder the ability to timely diagnose a considerable number of NCDs whose primary clinical profile differs from typical AD phenotype, also in light of the new evidence in favor of including socio-cognitive deficits as neuropsychological criterium for the diagnosis of the behavioral variant of frontotemporal dementia (bvFTD) [6], yet in prodromal phase [7], as well to better reach a correct differential diagnosis [8]. Despite advancement in theoretical and clinical research, this knowledge has not effectively translated into improved expertise or familiarity with socio-cognitive assessments among clinicians in memory clinics, highlighting a persistent gap between research and clinical practice [9, 10]. To address these challenges, the *SIGNATURE* initiative was launched in 2022, aiming to systematize and optimize the use of social cognition measures across different international clinical centers (<https://sites.google.com/units/nitn.it/signature-initiative/>). The ultimate goal of the *SIGNATURE* initiative is to ensure that clinicians, regardless of their location or resources, have access to reliable and effective tools for assessing social cognition in case of cognitive and behavioral complaints associated with suspected NCDs. In light of this, in 2022 we launched a survey to gather information on the state-of-art clinical practices and needs [11], laying the foundation for the next phase of the *SIGNATURE* initiative.

By providing clinical recommendations and suggestions on research priorities based on evidence from current literature and the state-of-the-art in clinics, the initiative seeks to promote consistency in clinical assessment, thereby improving the comparability of clinical research and findings across centers and the reliability of diagnoses. This ideally harmonized or at least consistent approach is expected to improve detection, patient care and care outcomes and to advance our understanding of social cognitive impairments in NCDs. The rationale for the *SIGNATURE* initiative is supported by analogous successful initiatives of harmonization of socio-cognitive assessments in other clinical populations, such as autism spectrum disorders (ASD) and schizophrenia. Over

10 years ago, the “Social Cognition Psychometric Evaluation” (SCOPE) study was designed to identify not only the key dimensions of social cognition in schizophrenia but also the instruments best assessing these facets [12]. Alongside the growing understanding of social and non-social cognitive dysfunctions in this population [13], the SCOPE initiative has led to a set of cognitive assessment recommendations from the European Psychiatric Association, many of which focus on social cognition [14]. These recommendations aim to promote the use of standardized assessment protocols in both clinical trials and real-world clinical settings. Building from the experience of similar initiatives, applying standardized socio-cognitive assessments in NCDs holds significant promise. Ideally harmonized or at least consistent recommendations can enhance the early detection of social cognitive impairments, which are often present in the prodromal stages of NCDs [7]. Moreover, early identification can lead to timely interventions on NCD patients and their caregivers, with crucial positive outcomes on quality of life. In fact, an increasing number of studies highlights that early identification of impairments in social cognition might predict negative outcomes in terms of worsening in functional activities (e.g., Chatzidimitriou et al. [16]; Hendel et al. [17]) quality of life [18], and reduced awareness of social functioning [19].

This paper describes the establishment of a task force with the objective of defining a framework and formulating a preliminary set of clinical recommendations pertaining to the context of use and the current relevance of socio-cognitive testing in mild and major NCDs. Additionally, it addresses the facilitators and obstacles to implementing this framework in clinical settings and suggests research priorities to support the development and implementation of social cognition assessment in NCD individuals.

Materials and methods

Task force

SIGNATURE Delphi team. The project task force included the Executive Board (EB), the Advisory Board (AB) and the panel (PA; details in Table 1). The EB included Delphi facilitators (C.C., A.D., G.F., C.M., A.P.) and one “external” reviewer (C.F.), one of the methodologists from the *SIGNATURE* initiative, who supervised the Delphi procedure. The AB included a scientific and methodological advisor (M.Bo.), 3 representatives from patient advocacy associations (L.I., M.P., M.T.) and an

Table 1 Participants and roles at the first *SIGNATURE* workshop (September 2023)

Name, SURNAME	Role in the Delphi Procedure	Role in the SIGNATURE initiative
The Executive Board		
Chiara CERAMI	Delphi Facilitator	Principal Investigator
Alessandra DODICH	Delphi Facilitator	Principal Investigator
Andrea PANZAVOLTA	Project Manager	Coordinating Team
Giulia FUNGHI	Delphi Facilitator	Coordinating Team
Claudia MELI	Delphi Facilitator	Coordinating Team
Cristina FESTARI	External Reviewer	Methodologist
The Delphi Panel		
Maxime BERTOUX	France Representative, Psychologist, Social Cognition Expert	Advisor
Fiona KUMFOR	Psychologist, Social Cognition Expert	Advisor
Jan VAN DEN STOCK	Belgium Representative, Psychologist, Social Cognition Expert	Advisor
Christian CHICHERIO	Switzerland-French section Representative, Psychologist, Clinical Researcher	National Collaborator
Florencia CLARENCE	Argentina Representative, Psychologist, Clinical Researcher	National Collaborator
Fabricio Ferreira de OLIVEIRA	Brazil Representative, Neurologist, Clinical Researcher	National Collaborator
Marco FILARDI	Italy Representative, Psychologist, Clinical Researcher	National Collaborator
Sarah MACPHERSON	UK Representative, Psychologist, Social Cognition Expert	National Collaborator
Jordi A. MATIAS-GUIU	Spain Representative, Neurologist, Clinical Researcher	National Collaborator
Maxime MONTEMBEAULT	Québec Representative, Psychologist, Clinical Researcher	National Collaborator
Leonardo SACCO	Switzerland-Italian section Representative, Neurologist, Clinical Researcher	National Collaborator
Ann-Katrin SCHILD	Germany Representative, Psychologist, Clinical Researcher	National Collaborator
Marc SOLLBERGER	Switzerland-German section Representative, Neurologist, Clinical Researcher	National Collaborator
Miguel TABUAS-PEREIRA	Portugal Representative, Neurologist, Clinical Researcher	National Collaborator
Esther VAN DEN BERG	The Netherland Representative, Psychologist, Social Cognition Expert	National Collaborator
Stefano CAPPÀ	Neurologist, Social Cognition Expert	Member
Agustin IBANEZ	ReDLat Representative, Psychologist, Social Cognition Expert	Member
Giancarlo LOGROSCINO	FRONTIERS Consortium Representative, Neurologist, Clinical Researcher	Member
Camillo MARRA	Italian Association of Neurology for dementia Representative, Neurologist, Clinical Researcher	Member
Costanza PAPAGNO	FESN Representative, Neurologist, Social Cognition Expert	Member
Olivier PIGUET	Psychologist, Social Cognition Expert	Member
Simone POMATI	INS cross-cultural needs working group Representative, Neurologist, Clinical Researcher	Member
The Advisory Board		
Marina BOCCARDI	Scientific & Methodological Advisor	Methodologist
Laura INVERNIZZI	FTD Caregiver Association Representative, World FTD United and AIMFT Italian FTD Association	Member
Mario POSSENTI	AD Caregiver Association Representative, Alzheimer Europe and Federazione Alzheimer Italia	Member
Magda TSOLAKI	AD Caregiver Association Representative, Greek Federation of Alzheimer's disease	Member
Marianna TSATALI	Expert of Neuropsychology Practice in people with disabilities	Member

expert (M.T.) in neuropsychology practices in people with disabilities.

Delphi panelists

The panel consists of specialists from different countries and scientific societies, i.e., 10 neurologists and 12 psychologists/neuropsychologists (Table 1). Thirteen experts are clinicians with both research and clinical experience in socio-cognitive assessment in NCDs and nine are researchers with world-renowned expertise in social cognition. Nine experts are national collaborators (representatives of countries participating in the SIGNATURE

initiative) and three are advisors (M.Be., E.K., J.VdS.) of the *SIGNATURE* initiative (see Participants section of the *SIGNATURE* website; <https://sites.google.com/un.itn.it/signature-initiative/participants>). All have a long professional experience in NCDs and in the use of social cognitive tasks for diagnostic purposes in the clinical practice of their academic and high-level research institutions. At the beginning of the activity, we presented the study objectives and timeline, and we asked participants to provide their informed consent for anonymous data collection.

Delphi methodology and procedure

In this project, we applied the Delphi methodology according to previously reported procedures [15, 20]. In detail, the EB reviewed the current literature and the results of the *SIGNATURE* clinical survey [11] and defined the panel for the Delphi procedure. Then, the facilitators drafted the first version of the Delphi questions, which was submitted to the external reviewer who assessed whether the items were sufficiently clear, neutral, informative, and complete. The Delphi questionnaire was then shared with all panelists via a web-based platform (i.e., Qualtrics) together with instructions to respond to each topic based on their expert opinion, experience, and evidence from the state-of-the-art. The Delphi procedure was performed during the 2-day hybrid First *SIGNATURE* Workshop held at the Scuola Universitaria Superiore IUSS in Pavia, Italy. Details of the event can be found at the following link <https://sites.google.com/unitn.it/signature-initiative/events/>. See Fig. 1 for details on the Delphi approach, including the preliminary activities and the Delphi procedure.

Delphi Questionnaire definition

The EB identified four target topics for the Delphi consensus assumptions aimed at defining: Clinical context of use and practice in socio-cognitive testing for the diagnosis of NCDs in memory clinics by specialists in dementia

(Section 1); Relevance of socio-cognitive assessment in cognitive decline and the dementia diagnostic framework (Section 2); Facilitators and obstacles for the implementation of socio-cognitive testing in clinics (Section 3); Priorities for future research on socio-cognitive testing in NCDs (Section 4). Agreement, multiple choice, relevance and open text questions were used to assess consensus assumptions. See Supplementary Table 1 for the full list of questions. Panelists were allowed to abstain from voting when the topic of the question was outside their area of expertise. All responses were substantiated with justifications.

Convergence threshold

For agreement and the multiple-choice questions, we established a predefined threshold of 70% of non-abstaining panelists for agreement in Round 1. Those questions for which no consensus was reached were then reformulated based on panelists' comments and presented in Round 2. In this case, an absolute majority (50% + 1) was sufficient for agreement. Responses to relevance questions were summed up into a single score and categorized according to the following range: ≥ 99 —*Very Important* (corresponding to a score of 'very important' assigned by at least half of the panelists, and the other half assigning a score of 'important'); $77 \leq x < 99$ —*Important* (corresponding to a score of 'important' assigned by at least




Fig. 1 Summary of the Delphi approach including preliminary activities (upper panel) and Delphi procedure (lower panel)

half of the panelists, and the other half assigning a score of 'neutral'); $55 \leq x < 77$ —*Neutral* (corresponding to a score of 'neutral' assigned by at least half of the panelists, and the other half assigning a score of 'not important'); $33 \leq x < 55$ —*Not Important* (corresponding to a score of 'not important' assigned by at least half of the panelists, and the other half assigning a score of 'not important at all'); < 33 —*Not Important At All* (when the majority of the panelists assigned a score of 'not important at all'). Open text questions were only used in Round 1 to derive a list of facilitators and obstacles that were voted on in terms of relevance during Round 2.

Evidence supporting the Delphi procedure

To help the Delphi panelists to make informed decisions, we provided them with the following background information: a) top-down evidence from a literature review on available socio-cognitive measures for the early and differential diagnosis of mild and major NCDs; b) bottom-up evidence derived from the results of our previous clinical survey [11].

Top-down evidence

For a), starting from a previous systematic review [21] that investigated clinically validated socio-cognitive measures for the diagnosis of behavioral variant of frontotemporal degeneration (bvFTD), we updated and expanded the literature review up to July 2023 according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [22]. We considered only original studies published in English, excluding reviews, case reports, and guidelines. Search strings were harmonized across NCD syndromes (mild or major) and etiological diagnosis (e.g., AD, FTD, etc.). See Supplementary Table 2 for details on search strings. Relevant references from personal knowledge and citation-tracking articles were also included. Titles and abstracts were screened, and potentially relevant studies were then examined according to the following criteria: 1) use of either a clinical or biomarker-based diagnosis for patient classification, 2) quantitative scoring of a socio-cognitive measure or social cognition battery; 3) availability of diagnostic accuracy data for socio-cognitive tests, including metrics such as sensitivity, specificity, accuracy, positive/negative predictive value, or positive/negative likelihood ratios. The quality of evidence was rated by A.D., C.C., A.P. and C.M. using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2, [23]), a tool designed to provide a formal assessment of the quality of primary studies included in a review to avoid bias. Raters were trained in QUADAS-2 and had fine-tuning methodological meetings to ensure uniformity and reproducibility of data extraction. Data

were recorded in an Excel spreadsheet, modified from Dodich et al., 2021 [21].

Bottom-up evidence

The SIGNATURE clinical survey results [11] were presented during the workshop and provided on a dedicated Google Drive folder to all the panelists prior to the Delphi Round 1 to inform them on the clinical evidence regarding the state-of-the-art of socio-cognitive assessment in memory clinics, the best-known and used tools for assessing social-cognitive function across ten European and non-European geographical areas, the perceived relevance of assessing social cognition in NCDs, and the hurdles envisioned for the use of socio-cognitive measures in real-life clinical scenarios.

Results

Top-down evidence

An updated literature review of studies on socio-cognitive measures available in clinics identified a total of 971 papers that were screened for subsequent processing (see Supplementary Fig. 1). After excluding duplicate records, wrong publication type and off-topic and non-English papers, only 65 papers were assessed for eligibility. Forty-four papers were excluded because: 1) only the combined diagnostic accuracy of social and other cognitive measures was reported, without specific information on the accuracy of social tasks; 2) accuracy values were calculated using multifactorial models from which the exclusive weight of the social cognition measures was not obtainable; or 3) mixed samples of mild/major NCDs were included. The remaining 21 papers provided validated measures of the accuracy of single or combined socio-cognitive measures in major NCDs, two of them also including mild NCDs (see Supplementary Table 3). Of these, ten studies explored the accuracy of tests of emotion recognition using facial stimuli (e.g., Ekman 60 faces test and its variants) [24–33], one test of emotional recognition using non-visual stimuli [34], eight using theory of mind tasks (Story-based Empathy Task, Reading the Mind in the Eyes test, the Faux-pas test, and experimental mentalizing music task) [26–29, 32, 35–37], eight using the Social Cognition and Emotional Assessment (SEA) battery or its short version (mini-SEA) [28, 29, 32, 38–42], and six using tests assessing other social cognition facets (e.g., empathy and socio-emotional sensitivity) [27, 33, 35, 38, 43, 44]. These papers reported good to excellent accuracy values for emotion recognition and theory of mind tasks in the early and differential diagnosis of bvFTD and good clinical performance in differentiating amnesic mild cognitive impairment (MCI) and AD versus healthy control subjects (HC). Only one study explored the clinical diagnostic performance of emotion recognition and theory of mind in

the differential diagnosis of frontotemporal lobar degeneration syndromes [26]. The quality of evidence assessed with QUADAS-2 was judged as strong in two studies [26, 38] showing an overall judgment of low risk of bias or low concern regarding applicability. Ten studies showed low/moderate risk of bias [24, 28, 29, 34, 36, 39–41, 43, 44]. The main methodological limitations were related to bias in: 1) patient selection (i.e., lack of consecutive, unspecified selection of subjects or inappropriate exclusions, $n=6$); 2) reference standards (i.e., either possible inaccurate to classify the target condition or low availability of in vivo biomarkers, $n=4$); and 3) flow and timing (i.e., unclear or inappropriate intervals between the index test(s) and the reference standard, and diagnoses not assessed against the same reference standard, $n=5$). See Supplementary Table 4 for a summary of the QUADAS-2 assessment for all included studies.

Bottom-up evidence

Results from the *SIGNATURE* survey data collection including 413 responses from 10 European and Latin America geographical regions reported the Ekman-60 faces (EK-60F; a well-known test for recognizing facial affect) test or its variants as the most well-known and used task overall, followed by two tests of theory of mind (i.e., the Faux-Pas and the Reading the Mind in the Eyes – RMET tests, or their variants) [11]. The EK-60F and the Faux-Pas tests were reported as known/used in 10/10 geographical regions, while the RMET in 8/10 [11]. In addition, the mini Social cognition & Emotional Assessment (Mini-SEA; a test combining facial emotion recognition and a selection of faux-pas) was known/used in 5/10 geographical regions and the Story-based Empathy task (SET; a test evaluating attribution of emotion and intention to others) in 6/10 [11].

Results of Section 1 – clinical context of use and practice

Two Delphi runs were performed. Regarding recommendations for clinical use, the panelists agreed that social cognition testing should be routinely included in the assessment of every patient as part of the diagnostic definition for NCDs (Round 1, Q1; votes: 86.4% of agreement). However, social cognition assessment in follow-up evaluations was recommended only for selected cases based on the presence of socio-cognitive deficits at the first assessment or based on symptoms reported at the follow-up visit (Round 2, Q2r; votes: 95.5% of agreement). First-level evaluation was voted as the most appropriate context for the assessment of social cognition in major (Q3) and mild (Q4) NCDs (Round 1, Q3: votes 81.8% of agreement; Q4: 90.9%). Socio-cognitive assessment should include at least two tests evaluating different facets of social cognition (Round 1, Q5; votes: 95.4% of agreement), that should be associated to a measure to

quantify changes in social behavior (e.g., sensitivity to social signals in real life) (Round 1, Q6; votes: 81.1% of agreement). See Fig. 2 for a summary of Section 1 recommendations and details on the agreement rates.

Results of Section 2 – relevance in NCD diagnosis

Panelists rated the assessment of emotion recognition in major NCDs (Round 1, Q7), and emotion recognition and cognitive ToM in mild NCDs (Round 1, Q8) as “very important”. The panel agreed on the use of the EK-60F test or its variants (Round 1, Q9; votes: 90% of agreement), the Faux-pas test (Round 2, Q10; votes 65% of agreement) and the Empathic Concern and Perspective Taking subscales of the Interpersonal Reactivity Index (IRI) questionnaire (Round 2, Q12r; votes: 57.9% of agreement) to assess emotion recognition, mentalizing, and empathy facets of social cognition respectively in major and mild NCDs. Panelists also agreed on using the RMET, the SET, and the mini-SEA as other tools to assess social cognition deficits in major and mild NCDs (Round 1, Q11; votes: 70% of agreement). No consensus was reached on using the revised version of the Self-monitoring Scale (r-SMS) to assess self-monitoring and awareness in NCDs. Specifically, the panelists recognized the evidence in favor of the use of r-SMS in frontotemporal dementia. However, based on the lack of information about the overall validity in mild and major NCDs, a consensus could not be found. Poor knowledge about the test and limited clinical data were raised as relevant points, which represent research priorities for its use in clinical practice. See Fig. 2 for a summary of the Section 2. Recommendations and Supplementary Fig. 2 for details on agreement rates.

Results of Section 3 – facilitators and obstacles

Clinical and methodological obstacles (e.g., lack of validated standardized tools, lack of normative data) emerged as the most relevant factors influencing the use of socio-cognitive measures in clinical practice, together with implementation hurdles (e.g., lack of professional socio-cognitive measure expertise and training for professionals, lack of time for the neuropsychological assessment) and external barriers (e.g., resistance to change in clinical practice, insufficient communication among research and clinical communities). Facilitators included the availability of tests with relatively low cognitive load in other cognitive domains, the availability of quick to administer cognitive tasks and the availability of cross-cultural and cross-language information. Automatization in data scoring and acquisition and lack of digital tools were rated only as marginal obstacles. See Fig. 3 for the full list of facilitators and obstacles.




Fig. 2 Clinical Applications and Relevance of Socio-Cognitive Assessment in NCDs. The figure lists recommendations for the clinical context of use and practice in socio-cognitive testing for the diagnosis of NCDs and on the relevance of socio-cognitive assessment in the different NCD diagnostic frameworks. See Supplementary Materials for details on the questions and agreement scores. *RMET*: Reading the Mind in the Eye Test; *SET*: Story-based Empathy task; *Mini-SEA*: mini-Social cognition & Emotional Assessment; *IRI-EC*: Interpersonal Reactivity Index – Empathic Concern; *IRI-PT*: Interpersonal Reactivity Index—Perspective Taking




Fig. 3 List of facilitators and obstacles identified with Section 3 questions. The figure shows in bold the facilitators and obstacles rated as “Very Important”, and in nonbold those rated as “Important”

Results of Section 4—priorities for future research

Considering priorities for future research, the panel agreed that social cognition assessment should include a subset of cognitive screening tests administrable remotely using digital tools but only if an in-person assessment is not possible (Round 2, Q15r; votes: 54.6% of agreement). The panel rated either patient- or informant-administered measures with supervision (Round 1, Q16) as “Important”. Tasks or interview administration without supervision were rated overall as less relevant. Tablet-based neuropsychology platforms and teleneuropsychology via videoconferencing were considered relevant scenarios in the diagnostic framework (Round 2, Q17) and in the follow-up neuropsychological evaluation (Round 2, Q18). Other digital tools, such as wearables, virtual/augmented reality and eye-tracking, were rated as less important.

Discussion

In this paper, we provide actionable recommendations to bridge the gap between research and clinical practice, advancing the implementation of socio-cognitive assessment within NCDs diagnostic procedures. As evidenced by the results of the *SIGNATURE* survey [11], the selection of social cognition measures is often influenced by individual clinical preferences, availability of measures, the level of expertise and local resources. This leads to significant differences in patient assessment and provision of care [45]. These recommendations aim to provide a general framework and guide the definition and implementation of social cognition assessment in NCDs.

Socio-cognitive testing is recommended for all patients suspected of mild or major NCDs during the baseline assessment to facilitate more accurate diagnosis. Moreover, it should be included in the follow-up neuropsychological evaluation of selected patients for better monitoring of the disease progression, based on the presence of socio-cognitive deficits at their initial assessment or on symptomatology reported at the follow-up clinical visit. Indeed, the DSM-5 recommendations support the assessment of social cognition; however, no specific details are provided for major/mild NCDs or differential frameworks (i.e., diagnostic or follow-up). The results of this study help to operationalize the DSM-5 guidelines based on current evidence and expertise in the field with a particular focus on patients whose presentation diverges from the typical Alzheimer's disease phenotype (i.e., amnesic syndrome of hippocampal type).

As suggested by the APA recommendations [46], which encourage that two tests provide a more comprehensive approach to accurately capture the multifaceted nature of cognitive domains, the panel agreed that socio-cognitive testing should include at least two tests that assess different facets of the social cognition domain, and that these

should be complemented by a measure that quantifies changes in social behavior. Indeed, the use of a single test to evaluate the complexity of social cognition changes in NCDs poses significant risks for inaccuracy or misinterpretation and may fail to capture the breadth of impairments across the various subdomains of social cognition. It should be noted, however, that the use of more than one test per cognitive domain may be limited in some clinical settings for reasons of feasibility concerns (e.g., lack of resources or time constraint) and that increasing the number of tests in the standard neuropsychological assessment may also rise the false-positive rates [47]. In this sense, the longitudinal assessment might help in detecting individuals with an objective deficit in socio-cognitive abilities from those without cognitive impairment falsely classified as impaired at baseline assessment. On the other hand, the lack of information about the index of change over time for socio-cognitive abilities in healthy adults, despite the available evidence of a progressive reduction in emotion recognition and theory of mind in adults over time [48], warrants caution in the interpretation of changes at follow-up assessment in clinical practice.

Different tests available in clinics were considered by the panel in terms of their current utility for the detection of social deficits. However, as pointed out by the panelists, some tools pose significant challenges, such as inadequate psychometric properties [46], including lack of information about possible fluctuations in cognitive performance, lack of normative data, longitudinal assessment of the performance trajectory. Besides the absence of cross-cultural validated tools hampers their harmonized use in memory clinics (for a list of tests available in different countries see *SIGNATURE* website in measures subsection). Future efforts should promote the development of more reliable tools, able to overcome these current limitations, possibly providing translations and cultural adaptations for different countries. This is a crucial point, as one could expect that social-cognitive measures—more than other cognitive domains—are heavily influenced by local specificities, social norms, and language nuances [49]. Variability in cultural contexts, characterized by different social norms, complex mental state definitions (e.g., *schadenfreude*) and non-verbal behaviors may lead to misinterpretations of individuals' performance if a test is used in a context other than that for which it was designed [50].

In this regard, it is important to note that most neuropsychological tasks have been developed and validated in Western, educated, industrialized, higher socio-economic status, and largely democratic countries. Applying these norms to individuals from societies or countries with very different social contexts can lead to misinterpretation and misdiagnosis of cognitive impairments. The

introduction of computerized adaptive testing through digital tools might advance the field of socio-cognitive testing by designing more flexible culture-broad tasks able to capture deficits in social cognition [51]. In addition, more inclusive practices in clinical neuropsychology would improve appropriateness of cognitive testing in sexual and gender minorities [52], since they could express vulnerabilities in socio-cognitive functioning, which remain currently unexplored [53, 54], as a consequence of specific environmental factors (e.g. stigma). Adapting socio-cognitive tools to reach a broader audience in clinics should also include populations with disabilities who have limited access to this type of evaluation [54]. Collaborative international participatory research, as also reported by the facilitators, is essential for addressing the challenges of social cognition assessment from a broad perspective, while also considering specific needs, such as those related to disabilities, and cultural differences.

Another key facilitator of socio-cognitive assessment is the definition of a clear conceptual and theoretical framework of social cognition. Increasing knowledge of how social cognition subdomains develop, function, and interact is a critical step in understanding the foundations of social behavior and how it can be measured in the clinical context of NCDs. Studies aimed at disentangling the interdependence of social cognition subdomains are needed to develop theoretical models from which neuropsychological batteries may be derived, as already available for other cognitive domains (e.g., the Birmingham Object Recognition Battery for visuo-spatial assessment [55]). Recent efforts to promote the use of consensual terminology [56], and other initiatives could help (e.g. Transdisciplinary EPND glossary). In addition to the above-mentioned clinical, methodological (e.g., cross-culturally validated tests with good psychometric properties) and implementation (e.g., brief socio-cognitive tasks feasible in clinical settings) priorities, other relevant factors in the use of socio-cognitive testing in clinical scenarios have been identified by the panelists. These include the presence of external factors such as the resistance to changing clinical practice and the availability of copyright-free tools. These issues deserve special attention and can be addressed in the context of multicenter projects. Besides, the cross-cultural translation of these results in other socio-cultural settings is still untested. International networks, such as those promoted by the Cognition Professional Interest Area (PIA) of the International Society to Advance Alzheimer's Research and Treatment (ISTAART PIA-Cognition), can help to raise awareness among multiple stakeholders.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13195-025-01908-2>.

Supplementary Material 1

Acknowledgements

This manuscript was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the Cognition professional interest area (PIA). The views and opinions expressed by authors in this publication represent those of the authors and do not necessarily reflect those of the PIA membership, ISTAART or the Alzheimer's Association. SIGNATURE workshop activities were supported by JPND call for expert Working Groups "Concepts for health and social care research for neurodegenerative diseases" and by Associazione Alzheimer Trento ODV. The 2nd International SIGNATURE workshop and SIGNATURE activities were supported by JPND call for expert Working Groups "Concepts for health and social care research for neurodegenerative diseases" (ANR-23-JPWG-0001 SIGNATURE) and by Associazione Alzheimer Trento ODV. SIGNATURE Initiative consortium (in alphabetical order): Federica Agosta, Samrah Ahmed, Ove Almkvist, Daniele Altomare, Alan Cronemberger Andrade, Davide Angioni, Jean-Marie Annoni, Francesca Baglio, Claudia Bartels, Peter Bekkhus-Wetterberg, Luca Beretta, Manfred Berres, Maxime Bertoux, Valentina Bessi, Marina Boccardi, Fabiola Böhm, Emre Bora, Renelle Bourdage, Helena Briaies, Andrea Brioschi-Guevara, Andreas Buchmann, Cinzia Bussè, Annachiara Cagnin, Elisa Canu, Stefano F. Cappa, Chiara Cerami, Russell Chandler, Thanos Chatzikostopoulos, Christian Chicherio, Lucy Chrisman-Russell, Maria Florencia Clarens, Alfredo Costa, Camille Coulangers, Chiara Cupidi, Fabricio Ferreira de Oliveira, Francesco Di Lorenzo, Mira Didic, Alessandra Dodich, Cem Dogdu, Renzo Dori, Bruno Dubois, Andrea Fabbo, Cristina Festari, Marco Filardi, Ingo Fimm, Bruno Fimm, Giulia Funghi, Douglas Galasko, Chiara Galli, Maurizio Gallucci, Gert Geurtsen, Anton Gietl, Nicola Girtler, Goran Hagman, Julie Henry, Agustín Ibanez, Laura Invernizzi, Sarah Isernia, Lize Jiskoot, Ingo Kilimann, Matthias Kliegel, Stefan Klöppel, Fiona Kumfor, Thibaud Lebouvier, Richard Levy, Marisa Lima, Giancarlo Logroscino, Antonina Luca, Simona Luzzi, Sarah MacPherson, Riccardo Manca, Valeria Manera, Gloria Mantineo, Pietro Marano, Marta Fernández Matarubia, Jordi A. Matias-Guiu, Patrizia Mecocci, Dix Meiberth, Claudia Meli, Nathalie Mella, Alina Menichelli, Micaela Mitolo, Andreas U. Monsch, Maxime Montembeault, Despoina Moraitou, Florentina Morello-Garcia, Silvana Morson, Flavio Nobili, Petr Novak, Anne Rita Oksengard, Miriam E. Ortiz, Pierre-Jean Ousset, Andrea Panzavolta, Sokratis Papageorgiou, Costanza Papagno, John Papatriantafyllou, Matteo Pardini, Rita Pezzati, Tommaso Piccoli, Martina Pigliautile, Olivier Piguet, Andrea Plutino, Simone Pomati, Jackie Poos, Mario Possenti, Davide Quaranta, Inez Ramakers, Pablo Reyes, Silvia Rodrigo Herrero, Elisa Ruiui, Mirella Russo, Leonardo Sacco, Perminder Sachdev, David P. Salmon, Pilar Sanchez, Nikolaos Scarmeas, Ann-Katrin Schild, Florian Schöberl, Matthias Schroeter, Haaro Seelaar, Stefano Sensi, Steven D. Shirk, Andrea Maria Slachevsky, Marc Sollberger, Marie Söntgerath, Fijanne Strijkert, Miguel Tãbuas-Pereira, Jennifer Thompson, Alessio Toraldo, Marianna Tsatali, Magda Tsolaki, Esther van den Berg, Jan Van den Stock, Hendrick-Jan van der Waal, Annalena Venneri, Susanna Vestberg, Tamlyn Watermeyer, Kathleen Anne Welsh-Bohmer, Bengt Winblad, Lucas Wolski, Nikki Zimmerman.

Authors' contributions

All authors (C.C., A.D., A.P., G.F., C.M., C.F., T.C., C.C., F.C., F.F.O., M.F., A.I., L.I., T.L., G.L., S.E.M., R.M., C.M., J.A.M.G., M.M., C.P., S.P., M.P., O.P., L.S., A.K.S., M.S., M.T.P., M.T., E.V.B., S.F.C., M.B., F.K., J.V.S., M.B., and K.A.W.B.) contributed to the study conception and design. Material preparation was performed by the Executive Board (C.C., A.D., A.P., G.F., C.M.). Data collection and analysis were performed by A.P., G.F., and C.M. The first draft of the manuscript was written by A.D. and C.C. All authors (C.C., A.D., A.P., G.F., C.M., C.F., T.C., C.C., F.C., F.F.O., M.F., A.I., L.I., T.L., G.L., S.E.M., R.M., C.M., J.A.M.G., M.M., C.P., S.P., M.P., O.P., L.S., A.K.S., M.S., M.T.P., M.T., E.V.B., S.F.C., M.B., F.K., J.V.S., M.B., and K.A.W.B.) reviewed the manuscript for content, read and approved the final version.

Funding

SIGNATURE workshop activities were supported by JPND call for expert Working Groups "Concepts for health and social care research for neurodegenerative diseases" and by Associazione Alzheimer Trento ODV.

Data availability

Datasets generated and analyzed in this study are available from the corresponding author on request.

Declarations

Ethics approval and consent to participate

The study protocol was approved by the IUSS University Ethics Committee (IUSS-University of Pavia; Protocol 104/22).

Consent for publication

Not applicable.

Competing interests

Stefano Cappa has received speaker honoraria from Biogen, Roche and Nutricia and is member of the Scientific Advisory Board of Brain Control. Chiara Cerami has been granted for consultancy by Newel Health, LinkForMed, Ethos, Biogen Italia, Eisai. Alessandra Dodich has received funding through her institution from Associazione Alzheimer Trento ODV. Cristina Festari has received funding through her institution from the Alzheimer's Association and Italian Ministry of Health. Giancarlo Logroschino has served as investigator for clinical trials sponsored by Biogen Pharmaceuticals, Axovant, Alector, Denali, Roche, Eisai, Genentech, Amylyx, Piam Farmaceutici SpA and has been granted for speech and consultancy by Eisai, Roche, Lilly, Piam Farmaceutici SpA, Biogen. Jordi Matias-Guiu has been granted for speech and consultancy by Almirall, Alter, Fujirebio, Esteve, KRKA and Schwabbe, Araclon, Eisai, and Schwabbe and is supported by grants from Instituto de Salud Carlos III and Fundacion Conocimiento Madri + D. Fabricio Ferreira de Oliveira has been granted for consultancy by Gerson Lehrman Group, Atheneum Partners, Guidepoint, Lionbridge. He is supported by FAPESP – The State of São Paulo Research Foundation (Grant #2015/10109–5) and is a board member of AAN Global Strategies Subcommittee, Awards Committee of the International Parkinson and Movement Society, ISTAART PIA Biofluid Based Biomarkers working group, ISTAART PIA Neuropsychiatric Syndromes and ESF Committee of Experts. Leonardo Sacco has served as investigator for clinical trials sponsored by Biogen and was member of the Advisory Board of Roche and Eisai. Agustín Ibanez is funded by ANID/FONDECYT Regular (1250091, 1210176, 1220995); ANID/FONDAP 15150012; ANID/PIA/ANILLOS ACT210096; ANID/FONDAP 15150012; Takeda CW2680521 and the Multi-Partner Consortium To Expand Dementia Research In Latin America [ReDLat, supported by Fogarty International Center (FIC) and National Institutes of Health, National Institutes of Aging (R01 AG057234, R01 AG075775, R01 AG21051, R01 AG083799, CARDS-NIH), Alzheimer's Association (SG-20-725707), Rainwater Charitable foundation – Tau Consortium, the Bluefield Project to Cure Frontotemporal Dementia, and Global Brain Health Institute]. The contents of this publication are solely the responsibility of the author and do not represent the official views of these institutions. The funders had no role in study design, data collection, analysis, publication decision, or manuscript preparation. Marc Sollberger has been granted for speech and consultancy by Lilly, Eisai, OM Pharma. Katheen Welsh-Bohmer is a consultant to WCG, Senaptec, Jigsawdio. She serves on the U.S. POINTER data safety monitoring board and is unpaid board member for the nonprofit Dementia Alliance of NC (DANC). She is also funded through US Federal Grants (NIA/NIH), NC DHHS state funds, and private foundational support (National Philanthropic Trust/Gates to the Alzheimer's Data Discovery Initiative ADDI). The other authors do not declare any conflict of interest.

Author details

¹Center for Mind/Brain Sciences - CIMeC, University of Trento, Rovereto, Italy

²IUSS Cognitive Neuroscience (ICoN) Center, Scuola Universitaria Superiore IUSS Di Pavia, Pavia, Italy

³Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy

⁴Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece

⁵Memory Center, Geneva University Hospitals, Geneva, Switzerland

⁶Memory and Aging Center, Fleni, Buenos Aires, Argentina

⁷Universidade Federal de São Paulo, São Paulo, Brazil

⁸University for Foreigners of Perugia, Perugia, Italy

⁹Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile

¹⁰Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland

¹¹Department of Biophysics, School of Medicine, Istanbul Medipol University, 34815 Istanbul, Türkiye

¹²Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005 Barcelona, Spain

¹³Cognitive Neuroscience Center (CNC), Universidad de San Andrés, Buenos Aires, Argentina

¹⁴Italian Frontotemporal Dementia Association, AIMFT, Brescia, Italy

¹⁵Université de Lille, Inserm, Centre Hospitalier Universitaire de Lille, Lille Neuroscience & Cognition, Lille, France

¹⁶Università Degli Studi Di Bari Aldo Moro, Bari, Italy

¹⁷Department of Psychology, The University of Edinburgh, Edinburgh, UK

¹⁸Department of Medicine and Surgery, University of Parma, Parma, Italy

¹⁹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

²⁰Department of Psychology – Catholic University of Sacred Heart, Milan, Italy

²¹Department of Neurology, Hospital Clinico San Carlos. San Carlos Health Research Institute (IdISSC), Universidad Complutense, Madrid, Spain

²²Douglas Research Centre & Department of Psychiatry, McGill University, Montreal, Canada

²³Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy

²⁴Federazione Alzheimer Italia, Milan, Italy

²⁵School of Psychology and Brain & Mind Centre, University of Sydney, Sydney, Australia

²⁶Neuropsychological and Speech Therapy Unit, Neurocenter of Southern Switzerland, Lugano, Switzerland

²⁷Universitätsklinikum Köln, Cologne, Germany

²⁸Memory Clinic, University Department of Geriatric Medicine FELIX PLATTER, Basel, Switzerland

²⁹Memory Clinic, Neurology Department, Centro Hospitalar E Universitário de Coimbra, Coimbra, Portugal

³⁰Faculty of Medicine, University of Coimbra, Coimbra, Portugal

³¹Department of Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the Netherlands

³²Lille Neuroscience & Cognition, Inserm U1172, Univ Lille, CHU Lille, France

³³School of Psychology, University of Sydney, Sydney, NSW, Australia

³⁴Neuropsychiatry, Leuven Brain Institute, KU Leuven, Leuven, Belgium

³⁵German Centre for Neurodegenerative Diseases (DZNE), Rostock-Greifswald Site, Rostock, Germany

³⁶Centre of Competence On Ageing, Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland

³⁷Department of Psychosomatic Medicine and Psychotherapy, University Medicine Rostock, 18147, Gehlsheimer Str. 20, Rostock, Germany

³⁸Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

³⁹Istituti Clinici Scientifici Maugeri IRCCS, Brain e-Health Aging Laboratory, Department of Neurorehabilitation, Milan, Italy

Received: 3 April 2025 / Accepted: 3 November 2025

Published online: 06 December 2025

References

1. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. Classifying neurocognitive disorders: the DSM-5 approach. *Nat Rev Neurol*. 2014;10:634–42. <https://doi.org/10.1038/nrneurol.2014.181>.
2. den Van Stock J. Social cognition assessment for mild neurocognitive disorders. *Alzheimers Dement*. 2022;18:1439–40. <https://doi.org/10.1002/alz.12475>.
3. Dodich A, Boccardi M, Sacco L, Monsch AU, Démonet J-F, Filardi M, et al. Answer to "Social cognition assessment for mild neurocognitive disorders." *Alzheimers Dement*. 2022;18:1441–2. <https://doi.org/10.1002/alz.12664>.
4. Van den Stock J, Bertoux M, Diehl-Schmid J, Piguet O, Rankin KP, Pasquier F, et al. Current Potential for Clinical Optimization of Social Cognition Assessment for Frontotemporal Dementia and Primary Psychiatric Disorders. *Neuropsychol Rev*. 2022. <https://doi.org/10.1007/s11065-022-09554-3>.

5. Dodich A, Cerami C. Answer to "Current Potential for Clinical Optimization of Social Cognition Assessment for Frontotemporal Dementia and Primary Psychiatric Disorders." *Neuropsychol Rev*. 2022. <https://doi.org/10.1007/s11065-022-09556-1>.
6. Piguet O, Clarke AJ, Foxe D, Tse NY, Teng H, Burrell JR, et al. Fourteen years later: reviewing the diagnostic criteria for behavioral-variant frontotemporal dementia. *Alzheimers Dement*. 2025;21:e70604. <https://doi.org/10.1002/alz.70604>.
7. Barker MS, Gottesman RT, Manoochehri M, Chapman S, Appleby BS, Brushaber D, et al. Proposed research criteria for prodromal behavioural variant frontotemporal dementia. *Brain*. 2022;145:1079–97. <https://doi.org/10.1093/brain/awab365>.
8. Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. *Brain*. 2020;143:1632–50. <https://doi.org/10.1093/brain/awaa018>.
9. Jarsch M, Semenikova A, Monsch A, Kressig R, Sollberger M. Eine Lücke, die es zu schließen gilt: Die Untersuchung sozial-kognitiver Fähigkeiten an deutschsprachigen Memory-Kliniken A Gap that Needs to be Closed: The Assessment of Social-Cognitive Abilities in German-Speaking Memory Clinics. *Z Neuropsychol*. 2022;33:129–37. <https://doi.org/10.1024/1016-264X/a000358>.
- 10.quesque F, Nivet M, Etchepare A, Wauquiez G, Prouteau A, Desgranges B, et al. Social cognition in neuropsychology: a nationwide survey revealing current representations and practices. *Appl Neuropsychol Adult*. 2022. <https://doi.org/10.1080/23279095.2022.2061859>.
11. Cerami C, Boccardi M, Meli C, Panzavolta A, Funghi G, Festari C, et al. Understanding barriers and optimizing socio-cognitive assessment in the diagnosis of neurocognitive disorders. *J Neuropsychol*. 2025;19:603–18. <https://doi.org/10.1111/jnp.12431>.
12. Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD. The social cognition psychometric evaluation study: results of the expert survey and RAND panel. *Schizophr Bull*. 2014;40:813–23. <https://doi.org/10.1093/schbul/sbt081>.
13. Green MF, Penn DL, Bental R, Carpenter WT, Gaebel W, Gur RC, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. *Schizophr Bull*. 2008;34:1211–20. <https://doi.org/10.1093/schbul/sbm145>.
14. Vita A, Gaebel W, Mucci A, Sachs G, Erfurth A, Barlati S, et al. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. *Eur Psychiatry*. 2022;65:e58. <https://doi.org/10.1192/j.eurpsy.2022.2316>.
15. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. *Health Technol Assess*. 1998;2:ii–iv, 1–88.
16. Chatzidimitriou E, Chen Y, Moraitou D, Ioannidis P, Aretouli E, Kramer JH, et al. The predictive value of social cognition assessment for 1-year follow-up functional outcomes in behavioral variant frontotemporal dementia. *J Neurol*. 2025;272:526. <https://doi.org/10.1007/s00415-025-13254-2>.
17. Hendel RK, Hellem MN, Larsen IU, Vinther-Jensen T, Hjermind LE, Nielsen JE, et al. Impairments of social cognition significantly predict the progression of functional decline in Huntington's disease: a 6-year follow-up study. *Appl Neuropsychol Adult*. 2024;31:777–86. <https://doi.org/10.1080/23279095.2022.2073824>.
18. Belfort T, Simões JP, Santos RL, Lacerda I, Dourado MCN. Social cognition: patterns of impairments in mild and moderate Alzheimer's disease. *Int J Geriatr Psychiatry*. 2020;35:1385–92. <https://doi.org/10.1002/gps.5379>.
19. Belfort T, Simões P, de Sousa MFB, Santos RL, Barbeito I, Torres B, et al. The relationship between social cognition and awareness in Alzheimer disease. *J Geriatr Psychiatry Neurol*. 2018;31:27–33. <https://doi.org/10.1177/0891988717743587>.
20. Festari C, Massa F, Cotta Ramusino M, Gandolfo F, Nicolosi V, Orini S, et al. European consensus for the diagnosis of MCI and mild dementia: preparatory phase. *Alzheimers Dement*. 2023;19:1729–41. <https://doi.org/10.1002/alz.12798>.
21. Dodich A, Crespi C, Santi GC, Cappa SF, Cerami C. Evaluation of discriminative detection abilities of social cognition measures for the diagnosis of the behavioral variant of frontotemporal dementia: a systematic review. *Neuropsychol Rev*. 2021;31:251–66. <https://doi.org/10.1007/s11065-020-09457-1>.
22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev*. 2021;10:89. <https://doi.org/10.1186/s13643-021-01626-4>.
23. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155:529–36. <https://doi.org/10.7326/0003-4819-155-8-201110180-00009>.
24. García-Casal JA, Martínez-Abad F, Cid-Bartolomé T, Smith SJ, Llano-Ordóñez K, Perea-Bartolomé MV, et al. Usability study and pilot validation of a computer-based emotion recognition test for older adults with Alzheimer's disease and amnesic mild cognitive impairment. *Aging Ment Health*. 2019;23(3):365–75. <https://doi.org/10.1080/13607863.2017.1423033>.
25. Diehl-Schmid J, Pohl C, Ruprecht C, Wagenpfeil S, Foerster H, Kurz A. The Ekman 60 faces test as a diagnostic instrument in frontotemporal dementia. *Arch Clin Neuropsychol*. 2007;22:459–64. <https://doi.org/10.1016/j.acn.2007.01.024>.
26. Dodich A, Crespi C, Santi GC, Luzzi S, Ranaldi V, Iannaccone S, et al. Diagnostic accuracy of affective social tasks in the clinical classification between the behavioral variant of frontotemporal dementia and other neurodegenerative disease. *JAD*. 2021;80:1401–11. <https://doi.org/10.3233/JAD-201210>.
27. Buhl C, Stokholm J, Gade A. Clinical utility of short social cognitive tests in early differentiation of behavioral variant frontotemporal dementia from Alzheimer's disease. *Dement Geriatr Cogn Disord Extra*. 2013;3:376–85. <https://doi.org/10.1159/000355123>.
28. Mariano LI, Caramelli P, Guimarães HC, Gambogi LB, Moura MVB, Yassuda MS. Can social cognition measurements differentiate behavioral variant frontotemporal dementia from Alzheimer's disease regardless of apathy? *JAD*. 2020;74:817–27. <https://doi.org/10.3233/JAD-190861>.
29. Moura MVB, Mariano LI, Teixeira AL, Caramelli P, De Souza LC. Social cognition tests can discriminate behavioral variant frontotemporal dementia from Alzheimer's disease independently of executive functioning. *Arch Clin Neuropsychol*. 2021;36:831–7. <https://doi.org/10.1093/arclin/aca084>.
30. Chiu I, Piguet O, Diehl-Schmid J, Riedl L, Beck J, Leyhe T, et al. Dissociation in rating negative facial emotions between behavioral variant frontotemporal dementia and major depressive disorder. *Am J Geriatr Psychiatry*. 2016;24:1017–27. <https://doi.org/10.1016/j.jagp.2016.06.011>.
31. Chiu I, Piguet O, Diehl-Schmid J, Riedl L, Beck J, Leyhe T, et al. Facial emotion recognition performance differentiates between behavioral variant frontotemporal dementia and major depressive disorder. *J Clin Psychiatry*. 2018;79:16m11342. <https://doi.org/10.4088/JCP.16m11342>.
32. Barbosa IG, Leite FDMC, Bertoux M, Guimarães HC, Mariano LI, Gambogi LB, et al. Social cognition across bipolar disorder and behavioral variant frontotemporal dementia: an exploratory study. *Braz J Psychiatry*. 2023. <https://doi.org/10.47626/1516-4446-2022-2935>.
33. Lichtenstein ML, Stewart PV, Kirchner HL, Finney G, Feldman HH. Exploring social cognition tests to differentiate frontotemporal dementia from depression: a two-step pilot study. *Alzheimer Dis Assoc Disord*. 2023;37:145–8. <https://doi.org/10.1097/WAD.0000000000000526>.
34. Amlerova J, Laczó J, Nedelska Z, Laczó M, Vyhňálek M, Zhang B, et al. Emotional prosody recognition is impaired in Alzheimer's disease. *Alzheimers Res Ther*. 2022;14:50. <https://doi.org/10.1186/s13195-022-00989-7>.
35. Gleichgerrcht E, Torralva T, Roca M, Manes F. Utility of an abbreviated version of the executive and social cognition battery in the detection of executive deficits in early behavioral variant frontotemporal dementia patients. *J Int Neuropsychol Soc*. 2010;16:687–94. <https://doi.org/10.1017/S1355617710000482>.
36. Downey LE, Blezat A, Nicholas J, Omar R, Golden HL, Mahoney CJ, et al. Mentalising music in frontotemporal dementia. *Cortex*. 2013;49:1844–55. <https://doi.org/10.1016/j.cortex.2012.09.011>.
37. Schroeter ML, Pawelke S, Bisenius S, Kynast J, Schuemberg K, Polyakova M, et al. A modified reading the mind in the eyes test predicts behavioral variant frontotemporal dementia better than executive function tests. *Front Aging Neurosci*. 2018;10:11. <https://doi.org/10.3389/fnagi.2018.00011>.
38. Custodio N, Montesinos R, Cruzado L, Herrera-Perez E, Failoc-Rojas VE, Pintado-Caipa M, et al. Social cognition and behavioral assessments improve the diagnosis of behavioral variant of frontotemporal dementia in older Peruvians with low educational levels. *Front Neurol*. 2021;12:704109. <https://doi.org/10.3389/fneur.2021.704109>.
39. Funkiewiez A, Bertoux M, de Souza LC, Lévy R, Dubois B. The SEA (social cognition and emotional assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. *Neuropsychology*. 2012;26:81–90. <https://doi.org/10.1037/a0025318>.
40. Bertoux M, Delavest M, de Souza LC, Funkiewiez A, Lépine J-P, Fossati P, et al. Social cognition and emotional assessment differentiates frontotemporal

- dementia from depression. *J Neurol Neurosurg Psychiatry*. 2012;83:411–6. <https://doi.org/10.1136/jnnp-2011-301849>.
41. Bertoux M, Funkiewiez A, O'Callaghan C, Dubois B, Hornberger M. Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. *Alzheimers Dementia*. 2013;9. <https://doi.org/10.1016/j.jalz.2012.09.010>.
 42. Bertoux M, de Souza LC, O'Callaghan C, Greve A, Sarazin M, Dubois B, et al. Social cognition deficits: the key to discriminate behavioral variant frontotemporal dementia from Alzheimer's disease regardless of amnesia? *J Alzheimers Dis*. 2016;49:1065–74. <https://doi.org/10.3233/JAD-150686>.
 43. Teichmann M, Daigormte C, Funkiewiez A, Sanches C, Camus M, Mauras T, et al. Moral emotions in frontotemporal dementia. *J Alzheimers Dis*. 2019;69:887–96. <https://doi.org/10.3233/JAD-180991>.
 44. Carr AR, Samimi MS, Paholpak P, Jimenez EE, Mendez MF. Emotional quotient in frontotemporal dementia vs. Alzheimer's disease: the role of socioemotional agnosia. *Cogn Neuropsychiatry*. 2017;22:28–38. <https://doi.org/10.1080/13546805.2016.1259612>.
 45. Henry JD, von Hippel W, Molenberghs P, Lee T, Sachdev PS. Clinical assessment of social cognitive function in neurological disorders. *Nat Rev Neurol*. 2016;12:28–39. <https://doi.org/10.1038/nrneurol.2015.229>.
 46. Higgins WC, Ross RM, Langdon R, Polito V. The "Reading the Mind in the Eyes" Test Shows Poor Psychometric Properties in a Large, Demographically Representative U.S. Sample. *Assessment*. 2023;30:1777–89. <https://doi.org/10.1177/10731911221124342>.
 47. Binder LM, Iverson GL, Brooks BL. To err is human: "abnormal" neuropsychological scores and variability are common in healthy adults. *Arch Clin Neuropsychol*. 2009;24:31–46. <https://doi.org/10.1093/arclin/acn001>.
 48. Grainger SA, Crawford JD, Riches JC, Kochan NA, Chander RJ, Mather KA, et al. Aging is associated with multidirectional changes in social cognition: findings from an adult life-span sample ranging from 18 to 101 years. *J Gerontol B Psychol Sci Soc Sci*. 2023;78:62–72. <https://doi.org/10.1093/geronb/gbac110>.
 49. Quesque F, Coutrot A, Cox S, de Souza LC, Baez S, Cardona JF, et al. Does culture shape our understanding of others' thoughts and emotions? An investigation across 12 countries. *Neuropsychology*. 2022;36:664–82. <https://doi.org/10.1037/neu0000817>.
 50. Isernia S, MacPherson SE, Baksh RA, Bergsland N, Marchetti A, Baglio F, et al. Italian adaptation of the Edinburgh Social Cognition Test (ESCoT): a new tool for the assessment of theory of mind and social norm understanding. *Front Psychol*. 2022;13:971187. <https://doi.org/10.3389/fpsyg.2022.971187>.
 51. Franzen S, European Consortium on Cross-Cultural Neuropsychology (ECCroN), Watermeyer TJ, Pomati S, Papma JM, Nielsen TR, et al. Cross-cultural neuropsychological assessment in Europe: position statement of the European Consortium on Cross-Cultural Neuropsychology (ECCroN). *Clin Neuropsychol*. 2022;36:546–57. <https://doi.org/10.1080/13854046.2021.1981456>.
 52. Anderson E, Eleazer J, Kristensen Z, St. Amand C, Baker A, Corroero A, et al. Affirmative neuropsychological practice with transgender and gender diverse individuals and communities. *Clin Neuropsychol*. 2022;1–19. <https://doi.org/10.1080/13854046.2022.2073915>.
 53. Zeilinger EL, Stiehl KAM, Weber G. A systematic review on assessment instruments for dementia in persons with intellectual disabilities. *Res Dev Disabil*. 2013;34:3962–77. <https://doi.org/10.1016/j.ridd.2013.08.013>.
 54. Manca R, Moreno JA, Nicoletti A, Henderson NJ, Flatt JD. Neurocognitive health in LGBTQIA+ older adults: current state of research and recommendations. *Front Hum Neurosci*. 2024;18:1394374. <https://doi.org/10.3389/fnhum.2024.1394374>.
 55. Riddoch JM, Humphreys GW. BORB: Birmingham Object Recognition Battery. Psychology Press; 2022. <https://doi.org/10.4324/9781003069645>.
 56. Quesque F, Apperly I, Baillargeon R, Baron-Cohen S, Becchio C, Bekkering H, et al. Defining key concepts for mental state attribution. *Commun Psychol*. 2024;2:1–5. <https://doi.org/10.1038/s44271-024-00077-6>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.